Eledon Pharmaceuticals Inc.

Last updated September 27, 2026

Organization details

Legal name
Eledon Pharmaceuticals Inc.
Former names
Novus Therapeutics, Inc. Tokai Pharmaceuticals Inc
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Irvine
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
ELDN
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001404281

Board of directors

Chief executives

David-Alexandre C. Gros · Chief Executive Officer
Dates unknown

Director election results

Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

4 of this board's directors also sit on 7 other boards. 7 are in the same sector.

Network of Eledon Pharmaceuticals Inc.'s board connections Emergent BioSolutions Inc. Emergent BioSolutions... Neurocrine Biosciences Inc. Neurocrine Biosciences... Rigel Pharmaceuticals Inc. Rigel Pharmaceuticals... Syndax Pharmaceuticals Inc. Syndax Pharmaceuticals... Tenaya Therapeutics Inc. Tenaya Therapeutics In... Travere Therapeutics Inc. Travere Therapeutics I... UroGen Pharma Ltd. UroGen Pharma Ltd. Gary A. Lyons Gary A. Lyons James A. Robinson Jr. James A. Robinson Jr... June Lee June Lee Keith Katkin Keith Katkin Eledon Pharmaceuticals Inc...
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Jul 31, 2026 Steven Perrin Director, Officer (President) Grant or award +152,353 — —
Jul 31, 2026 David-Alexandre C. Gros Director, Officer (Chief Executive Officer) Grant or award +354,454 — —
Jul 31, 2026 Steven Perrin Director, Officer (President) Shares withheld for tax −72,138 $3.38 $243,826
Jul 31, 2026 David-Alexandre C. Gros Director, Officer (Chief Executive Officer) Shares withheld for tax −194,791 $3.38 $658,394
Jan 10, 2026 John S. McBride Director Option exercise +3,430 — —
Jan 10, 2026 Jan Hillson Director Option exercise +3,430 — —
Jan 10, 2026 Allan Kirk Director Option exercise +3,430 — —
Jan 10, 2026 Keith Katkin Director Option exercise +8,575 — —
Jan 10, 2026 June Lee Director Option exercise +3,430 — —
Jan 10, 2026 James A. Robinson Jr. Director Option exercise +3,430 — —
May 9, 2024 BVF INC/IL 10% owner Open-market purchase +1,031,385 — —
May 9, 2024 BVF INC/IL 10% owner Open-market purchase +821,121 — —
May 9, 2024 BVF INC/IL 10% owner Open-market purchase +75,431 — —
May 5, 2023 Biotechnology Value Trading Fund OS LP See Explanation of Responses Open-market purchase +1,055,445 — —
May 5, 2023 Biotechnology Value Trading Fund OS LP See Explanation of Responses Open-market purchase +837,146 — —

Organizations in the same sector, closest in location and size first.

Questions about Eledon Pharmaceuticals Inc.

Who is the CEO of Eledon Pharmaceuticals Inc.?

David-Alexandre C. Gros is Eledon Pharmaceuticals Inc.'s Chief Executive Officer.

How many directors are on Eledon Pharmaceuticals Inc.'s board?

Eledon Pharmaceuticals Inc.'s board has 10 directors: Allan Kirk, David-Alexandre C. Gros, Gary A. Lyons, James A. Robinson Jr., Jan Hillson, John S. McBride, June Lee, Keith Katkin, Steven Perrin and Walter C. Ogier.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="eledon-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.